 SDGR has fallen nearly 50 since our first publication in May and nearly 70 from its high. However, we believe this drawdown presents the best risk-reward entry since the IPO. The fall has been primarily driven by factors outside the business. Investors in 2021 turned away from biotech, growth, and high multiple stocks, of which SDGR is all three. 